

Genome-wide association studies and multi-omics integrative analysis reveal novel loci and their molecular mechanisms for circulating polyunsaturated, monounsaturated, and saturated fatty acids

Yitang Sun¹, Huifang Xu¹, Kaixiong Ye^{1,2,*}

¹Department of Genetics, University of Georgia, Athens, GA, USA

²Institute of Bioinformatics, University of Georgia, Athens, GA, USA

* Correspondence: Dr. Kaixiong Ye (Kaixiong.Ye@uga.edu)

1 **Abstract**

2 **Background:** Dietary and circulating levels of polyunsaturated fatty acids (PUFAs) have been
3 associated with mortality and risks of various diseases. The circulating levels of fatty acids (FAs)
4 exhibit heterogeneity across individuals due to genetic and environmental influences. Although
5 previous genome-wide association studies (GWAS) have identified genetic loci associated with
6 FAs, the biological mechanisms of these genetic associations remain largely unexplored.

7 **Methods:** Here, we conducted GWAS to identify additional genetic loci for 19 circulating fatty
8 acid (FA) traits, quantified by nuclear magnetic resonance spectroscopy, in UK Biobank
9 participants of European ancestry (N = 239,268) and five other ancestries (N = 508 – 4,663). We
10 leveraged the GWAS findings to characterize genetic correlations and colocalized regions among
11 FAs, explore sex differences, examine FA loci influenced by lipoprotein metabolism, and apply
12 statistical fine-mapping to pinpoint putative causal variants. The integrative analysis of GWAS
13 and multi-omics quantitative trait loci (QTL) reveals intermediate molecular phenotypes mediating
14 the associations between the genetic loci and FA levels.

15 **Results:** Altogether, we identified 215 significant loci for PUFAs-related traits in European
16 participants, 163 loci for monounsaturated fatty acids (MUFAs), and 119 loci for saturated fatty
17 acids (SFAs), including 70 novel loci for PUFAs, 61 for MUFAs, and 54 for SFAs. Of these
18 significant loci, a novel locus for total FAs, omega-6 PUFAs relative to total FAs, and total
19 MUFAs (around genes *GSTT1/2/2B*) overlapped with QTL signals for all six molecular
20 phenotypes examined, including gene expression, protein abundance, DNA methylation, splicing,
21 histone modification, and chromatin accessibility. Across FA traits, 65% of GWAS loci
22 overlapped with QTL signals for at least one molecular phenotype.

23 **Conclusions:** Our study identifies additional novel genetic loci and provides the first evidence
24 uncovering molecular mechanisms underlying FAs-relevant variants. These findings offer insights
25 that could facilitate patient stratification for precision nutrition.

26

27 **Keywords:** GWAS, polyunsaturated fatty acids, fatty acids, xQTL, multi-omics

28 **Introduction**

29 Polyunsaturated fatty acids (PUFAs), monounsaturated fatty acids (MUFAs), and saturated
30 fatty acids (SFAs) have been implicated in various diseases.¹⁻³ Evidence from epidemiological and
31 genetic studies indicates that PUFAs, especially omega-3 PUFAs, are associated with reduced
32 risks of various diseases or mortality by modifying metabolism and inflammation.⁴⁻⁷ Circulating
33 fatty acid (FA) levels are influenced by environmental and genetic factors and characterized by
34 sex- and ancestry-specific patterns.⁸⁻¹⁰ Dietary intake, socioeconomic status, physical inactivity,
35 cigarette smoking, and alcohol consumption are common environmental factors that influence FA
36 levels.¹¹ Although hundreds of genetic loci associated with FAs have been identified by genome-
37 wide association studies (GWAS),¹²⁻³⁷ the biological mechanisms of these genetic associations
38 remain largely unexplored. Moreover, these genetic loci were mainly discovered in the European
39 (EUR) population and were focused on autosomes. Extending GWAS to non-EUR populations
40 and sex chromosomes will offer a comprehensive understanding of the genetic architecture of
41 circulating FAs.

42 In this study, we performed GWAS for 19 FA traits related to PUFAs, MUFAs, and SFAs
43 to identify more novel genetic loci. We conducted overall and sex-specific GWAS using 250,101
44 individuals of EUR ancestry and five other ancestries from the UK Biobank (UKB). Leveraging
45 the GWAS summary statistics, we characterized heritability for these FA traits and examined their
46 shared genetic basis with genetic correlation and colocalization analysis. Candidate causal variants
47 were pinpointed with statistical fine-mapping. Finally, we integrated GWAS signals with multi-
48 omics data to identify the mediating molecular phenotypes and provide mechanistic insights into
49 the molecular mechanisms underlying the GWAS signals.

50 **Materials and Methods**

51 **Participants**

52 The UKB cohort is a prospective population-based study of ~500,000 participants from
53 across the United Kingdom, aged between 37 and 73 years at recruitment from 2006 to 2010.³⁸ Of
54 the individuals with both phenotype and genotyping data, we excluded participants who have
55 withdrawn consent, mismatched information between phenotypic and genetic sex, sex
56 chromosome aneuploidy, or are outliers for heterogeneity and missing genotype rate. Genetic
57 ancestry groups have been previously defined in the Pan-ancestry genetic analysis of the UK
58 Biobank (Pan-UKB).³⁹ Together, we included up to 239,268 participants of EUR ancestry in this
59 study. We also included participants of African (AFR) (N = 3,352), admixed American (AMR)
60 (N = 508), Central/South Asian (CSA) (N = 4,663), East Asian (EAS) (N = 1,445), and Middle
61 Eastern (MID) (N = 865) ancestries. Table S1 provides the overall and sex-stratified characteristics
62 of participants in each ancestry group. This study received ethical approval from the National
63 Health Service North West Centre for Research Ethics Committee, and all participants provided
64 informed consent. Data from the UKB resource were accessed under application number 48818.

65 **Phenotypes – circulating fatty acids (FAs)**

66 Plasma FAs were measured in a randomly selected subset of 274,020 participants by
67 Nightingale Health using nuclear magnetic resonance (NMR) spectroscopy.⁴⁰ All FA levels and
68 their ratios were normalized within each ancestry group using the rank-based inverse normal
69 transformation in overall GWAS.⁴¹ This inverse normal transformation was applied separately for
70 males and females to account for sex-specific differences in FA distributions. In total, 20 metabolic
71 measurements were analyzed in the GWAS including total FAs, 5 PUFA absolute concentrations
72 (i.e., PUFAs, omega-3 PUFAs, omega-6 PUFAs, docosahexaenoic acid (DHA), and linoleic acid

73 (LA)), their relative percentages in total FAs (i.e., PUFAs%, omega-3%, omega-6%, DHA%, and
74 LA%), the ratio of omega-3 to omega-6 PUFAs (omega-3/omega-6), the ratio of omega-6 to
75 omega-3 PUFAs (omega-6/omega-3), monounsaturated fatty acids (MUFAs), saturated fatty acids
76 (SFAs), MUFAs%, SFAs%, PUFAs/MUFAs, PUFAs/SFAs, and degree of unsaturation. Both the
77 omega-3/omega-6 ratio and omega-6/omega-3 ratio were included in our GWAS due to different
78 preferences in the field, but they revealed the same genetic loci in opposite effect directions. In
79 additional analyses, we focused on omega-3/omega-6 and did not include omega-6/omega-3,
80 resulting in a total of 19 plasma metabolic measurements.

81 **Genotyping and quality control**

82 Full details about genotyping, imputation, and genotype-based quality control (QC) have
83 been described elsewhere.⁴² Briefly, we excluded variants with imputation quality score < 0.3,
84 minor allele frequency < 0.001, genotype missingness per variant > 0.05, and Hardy-Weinberg
85 test P -value < 1×10^{-8} . We also confirmed that no individuals have genotype missingness > 0.05.
86 For the non-pseudoautosomal region of the X chromosome (GRCh37; chrX: 2699520-154931044),
87 males were treated as homozygotes of the reference or effect allele, and coded as 0 or 2,
88 respectively.

89 **Genome-wide association studies (GWAS)**

90 Overall GWAS were conducted for each ancestry group and followed by sex-stratified
91 GWAS. We carried out GWAS in participants of EUR ancestry using fastGWA from the GCTA
92 toolbox (v.1.94.1), which controls for familial relatedness using a sparse genetic relationship
93 matrix (GRM) with a default threshold of 0.05 based on slightly linkage disequilibrium (LD)-
94 pruned HapMap3 variants.^{43,44} Considering the relatively small sample size for other ancestry
95 groups (AFR, AMR, CSA, EAS, and MID), the mixed-linear-model association (MLMA) method

96 was used to perform GWAS using a dense GRM.⁴⁵ Additionally, sex-specific GWAS were
97 conducted for each ancestry group using fastGWA for EUR participants and MLMA for other
98 ancestry groups, excluding sex as a covariate from all models.

99 To explore the influences of potential covariates, we performed GWAS in the EUR
100 ancestry participants using 3 models. In model 1, we included age, sex, age \times sex, and the top 10
101 genetic principal components derived from the Pan-UKB as covariates. Model 2 added additional
102 covariates, including body mass index, Townsend deprivation index, smoking status, alcohol
103 status, physical activity, and statin use.^{46,47} In model 3, we adjusted for fish oil supplementation
104 status and lipoprotein lipids including chylomicron, very-low-density lipoprotein (VLDL),
105 intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), high-density lipoprotein
106 (HDL) cholesterol as additional covariates. For GWAS in the non-EUR population, we applied
107 models 1 and 2.

108 **Identification of novel loci**

109 To identify novel loci, we compared our independent loci to the previously reported FA
110 loci in the GWAS Catalog and in other relevant publications identified by literature review up until
111 June 2024.⁴⁸ Independent loci were identified in our results or previous GWAS based on genome-
112 wide significance threshold (P -value $< 5 \times 10^{-8}$) and LD-based clumping ($r^2 = 0.1$, window size =
113 250 kb) using PLINK.^{49,50} Independent loci were merged based on proximity (± 250 kb). We
114 annotated the lead variants for their target genes and functional consequences using the Ensemble
115 GRCh37 Variant Effect Predictor (VEP).⁵¹

116 **Heritability and genetic correlation analyses**

117 Heritability and genetic correlations were estimated with linkage disequilibrium score
118 regression (LDSC) in the EUR ancestry subset.^{52,53} In-sample LD scores were derived from

119 [s3://broad-alkesgroup-ukbb-ld/UKBB_LD/](https://broad-alkesgroup-ukbb-ld/UKBB_LD/).⁵⁴ As recommended, we checked for inflation using
120 the attenuation ratio in the EUR population and genomic inflation factor (λ_{GC}) in other
121 populations.⁵⁵

122 **Colocalization with FA traits**

123 We performed colocalization analysis with HyPrColoc (v.1.0) to assess whether two or
124 more FA traits share a putative causal variant.⁵⁶ Pairwise and multi-trait colocalization analyses
125 were conducted for each pair or all FA traits altogether. We used the default priors, including the
126 probability of a variant being associated with a single trait ($\text{prior.l} = 1 \times 10^{-4}$) and the conditional
127 probability of association with an additional trait ($\text{prior.c} = 0.02$). A posterior probability (PP) >
128 0.8 was considered as evidence for a shared causal variant.

129 **Statistical fine-mapping of GWAS loci**

130 To identify the most plausible causal variants for genome-wide significant loci associated
131 with each FA trait, we used SuSiE (v.0.12.27).⁵⁷ We used the 1 Mb region surrounding the lead
132 variant of each genetic locus for statistical fine-mapping. We utilized in-sample LD information
133 to estimate the correlations among SNPs. The 95% credible set identified potential causal variants
134 based on their PP. Only variants with a PP > 0.8 were reported, with higher PP values closer to 1
135 indicating more likely to be causal variants.

136 **Gene-based and gene-set analyses**

137 MAGMA v.1.08, implemented in FUMA, was used to perform gene-based and gene set
138 analyses.^{58,59} In the gene-based analysis, 19,665 SNPs were linked to protein-coding genes, and
139 Bonferroni correction was applied to establish the significance threshold ($P < 0.05/19,665 = 2.54$
140 $\times 10^{-6}$). We determined the enrichment of candidate FA-associated genes in specific biological
141 pathways, cellular components, or molecular functions. A total of 15,481 gene sets (5,497 curated

142 gene sets and 9,984 gene ontology terms) obtained from MsigDB were tested, with the Bonferroni-
143 corrected significance threshold set at $P < 3.23 \times 10^{-6}$.⁶⁰

144 **Omics PIEiotRopic Association (OPERA) analysis**

145 To provide mechanistic interpretations of FA-associated variants, we performed an
146 integrative analysis of six types of multi-omics quantitative trait loci (QTL) summary statistics
147 with GWAS signals using the Bayesian method, Omics PIEiotRopic Association (OPERA).⁶¹ First,
148 we obtained available molecular quantitative trait loci (xQTL) data, including gene expression
149 QTL (eQTL), protein QTL (pQTL), DNA methylation QTL (mQTL), splicing QTL (sQTL),
150 histone modification QTL (hQTL), and chromatin accessibility QTL (caQTL). We downloaded
151 blood *cis*-eQTLs summary statistics generated from the eQTLGen study (N = 31,684).⁶² The
152 plasma pQTL summary statistics were retrieved from the UKB Pharma Proteomics Project (UKB-
153 PPP) using UKB participants (N = 54,219).⁶³ The peripheral blood mQTL data were generated by
154 McRae *et al.* (N = 1,980).^{64,65} We derived summary-level sQTL data from whole blood samples in
155 the Genotype Tissue Expression (GTEx) Project v.8 (N = 670).⁶⁶ The H3K27ac and H3K4me1
156 hQTL in monocytes were generated from the BLUEPRINT project (N = 200).⁶⁷ The caQTL data
157 in lymphoblastoid cell line samples were estimated by Kumasaka *et al.* (N = 100).⁶⁸ We included
158 the molecular phenotypes with at least one xQTL with $P < 5 \times 10^{-8}$ and excluded the major
159 histocompatibility complex (MHC) region due to its structural complexity. After filtering
160 molecular phenotypes, we retained 15,785 genes, 2,190 proteins, 94,338 DNA methylation sites,
161 6,639 RNA splicing events, 18,152 histone marks, and 13,873 chromatin accessibility peaks. The
162 posterior probability of association (PPA) threshold of 0.9 and the multi-exposure heterogeneity
163 in dependent instruments (HEIDI) test threshold of 0.01 were used to determine if a GWAS signal
164 overlaps with the QTL signals for one or multiple molecular phenotypes.

165 **Results**

166 **Sample characteristics**

167 The primary GWAS study comprised up to 239,268 individuals of EUR ancestry. GWAS
168 were also conducted on five additional ancestry groups, including up to 3,352 AFR, 508 AMR,
169 4,663 CSA, 1,445 EAS, and 865 MID individuals. Among EUR participants, the average age was
170 57 years and females were more likely to have higher PUFA levels (Table S1). The percentage of
171 female participants in EUR, AFR, AMR, CSA, EAS, and MID populations was 53.9%, 59.7%,
172 66.9%, 44.8%, 64.6%, and 41.8%, respectively. Approximately 31.6% of individuals reported
173 regular use of fish oil supplements and the ratio of omega-3/omega-6 was around 1:8.

174 **Identification of genome-wide significant loci for FAs**

175 We first performed EUR ancestry GWAS for each FA trait using three models, respectively.
176 Since we are particularly interested in the genetic architecture of FA traits in the category of
177 PUFAs, we primarily use results in this category as examples throughout this article to demonstrate
178 our findings. Similar results for FA traits in the categories of MUFAs and SFAs are available in
179 supplementary materials. Figure 1A shows a Manhattan plot of GWAS for the absolute
180 concentration of total PUFAs in model 2. Table S2 reports the number of significant loci for each
181 FA from all GWAS across all models. Using model 2, we identified 122 independent genetic loci
182 for the category of PUFAs, 124 for MUFAs, and 102 for SFAs; however, only 46, 39, and 38 loci
183 respectively associated with these categories of FA traits in model 3 (Table S2). (Please elaborate
184 a bit more. Are all loci in model 3 identified in model 2? If not, how many were identified in model
185 2? Then, the rest is only significant in model 3.) A total of 92 loci identified in model 2 were no
186 longer significantly associated with total PUFAs after adjusting for fish oil intake and lipoprotein
187 lipids in model 3 (Figure 1B). We observed similar effect estimates between models 1 and 2,

188 whereas model 3 yielded systematically larger effect estimates than those from the other two
189 models (Figure S1). To further explore the distinction between models 3 and 2, we conducted
190 GWAS based on model 2 by additionally adjusting for fish oil supplementation in model 2.1 and
191 for lipoprotein lipids in model 2.2. The differences in GWAS results between model 3 and the
192 others were attributed to the additional adjustment for lipoprotein lipids (Table S2). For example,
193 variants in the *LDLR* and *MTTP* genes, known for their strong correlation with lipoprotein
194 lipids,^{69,70} were significant in model 2 but not in model 3.

195 Regarding SNP-based heritability of FA traits in the EUR population, we found that SNPs
196 explained 5–19% of the phenotypic variance for all FA traits across all three models (Figure S2A;
197 Table S3). For instance, the SNP-based heritability estimates for the absolute concentrations of
198 total PUFAs, MUFAs, and SFAs were 19%, 19%, and 16%, respectively, in model 2. The genomic
199 inflation factor (λ_{GC}) for all GWAS ranged from 1.07 to 1.29 (Table S4). The attenuation ratio
200 ranged from 0.03 to 0.18, and the LDSC intercept ranged from 1.01 to 1.12, suggesting that the
201 genome-wide elevation of association statistics was primarily due to true additive polygenic effects
202 rather than confounders such as population stratification.

203 To identify novel loci, we searched the literature and GWAS Catalog to compile known
204 loci for FAs-related traits, making it the most comprehensive collection to date (Table S5). When
205 categorizing FA traits into PUFAs-related, MUFAs-related, and SFAs-related, we identified 70,
206 61, and 54 novel loci among 215, 163, and 119 significant loci, respectively, with model 2 (Table
207 S6). The numbers of novel loci for each FA trait are provided in Table S7. Compared with all
208 previously reported FAs-related loci, the top 10 strongest novel loci identified across all FA traits
209 in model 2 were mapped to candidate genes including *PEPD*, *SBNO1*, *IL1RN*, *INSIG2*, *VIM*, *PGS1*,
210 *ARID5B*, *NF1*, *FAM96A*, and *PEX6* (Table S8). We also compared independent loci to those

211 previously reported in GWAS for the same traits. The novel locus *VEGFA* was associated with
212 total FAs, LA%, SFAs, PUFAs/SFAs, and the degree of unsaturation in our study, and it was
213 consistently associated with MUFAs, MUFAs%, and PUFAs/MUFAs in both our and previous
214 GWAS.^{29,32,33,37} Variants in *GCKR* were found to be significantly associated with DHA% for the
215 first time, consistent with previous GWAS findings for other FA traits.

216 Additionally, we explored genetic associations on the X-chromosome in both overall and
217 sex-specific GWAS. Previously, only one GWAS identified FA loci on the X-chromosome.²⁹ That
218 GWAS reported two X-chromosomal loci associated with FA traits; however, no significant
219 variants were identified in our overall GWAS. When evaluating males separately, one significant
220 association with omega-3% was found on the X-chromosome.

221 **Sex-specific FA GWAS**

222 We then stratified the total sample by sex to perform sex-specific GWAS separately for
223 128,922 females and 110,346 males in the EUR population. Approximately 4.2% of the significant
224 loci from sex-specific GWAS were not identified in the overall GWAS (Table S7). The SNP-based
225 heritability ranged from 5% to 21% in females and 4% to 20% in males, and there was no evidence
226 of genomic inflation (Figures S2B and S2C; Table S3). In model 2, we identified 128 independent
227 loci associated with PUFAs-related traits in females and 106 loci in males, including 27 and 8
228 novel loci, respectively, which have not been reported in previous GWAS of PUFAs-related traits
229 (Table S6). GWAS results for both known and novel loci associated with each FA trait are
230 provided in Table S9 for females and Table S10 for males. Interestingly, among the three novel
231 loci associated with PUFAs compared to previous GWAS related to all FA traits, two loci mapped
232 to *RNU6-1180P* and *KRT18P55* were significant only in females from model 2 (Figure 2). After
233 accounting for lipoprotein lipids, three additional novel loci for PUFAs, around gene *UNC5CL*,

234 *RP11-328J6.1*, and *SIPAIL3*, were identified in females and no novel locus in males was identified
235 when comparing with all previous FA GWAS in model 3 (Figure S3). In the sex-specific GWAS,
236 we found that approximately 43% of the genome-wide significant loci identified in models 1 and
237 2 were not identified in model 3 (Table S7). Notably, one X-chromosomal locus associated with
238 omega-3%, whose lead SNP is rs147828433, was identified from GWAS using model 2 in males.
239 Our study is the first to explore loci in sex-specific GWAS and to include the X chromosome.

240 **GWAS for FA traits in individuals of non-EUR ancestries**

241 Across all FA traits, we identified 38 significant loci in ancestry-specific GWAS, of which
242 23 are novel compared to previous studies in EUR and non-EUR populations (Table S11). The
243 genomic inflation factor (λ_{GC}) was also reported for each non-EUR ancestry, with average λ_{GC}
244 values of 0.97, 0.92, 0.99, 0.90, and 0.95 for AFR, AMR, CSA, EAS, and MID, respectively
245 (Tables S4). In the non-EUR ancestry GWAS, the most significant locus was around *FADS2*,
246 identified in four ancestry groups except AFR, which is a well-known locus in the EUR population
247 (Table S11). Among non-EUR populations, CSA had the largest sample size, leading to more loci
248 being identified compared to other groups, with 1–4 loci in model 1 and 0–2 in model 2 (Table
249 S2). The GWAS in CSA male participants identified a novel locus *EDNI* associated with total
250 PUFAs, omega-6 PUFAs, and LA, while this locus did not reach the genome-wide significance in
251 the EUR population. In addition, variants in *VPS39*, which had not been reported in previous
252 GWAS, were associated with total PUFAs, omega-6 PUFAs, and LA in both total and male-only
253 CSA participants.

254 **Genetic correlations among FA traits**

255 We examined genetic correlations (r_g) between FA traits using EUR GWAS summary
256 statistics from three models (Table S12). Broadly, comparisons of genetic correlations between

257 models revealed similar estimates for models 1 and 2 but distinct estimates when compared to
258 model 3, as illustrated in Figure S4. Among the 171 pairs of genetic correlations, 14 pairs that had
259 significantly negative genetic correlations in models 1 and 2 became significantly positive in
260 model 3, while four pairs that were significantly positive in models 1 and 2 became significantly
261 negative in model 3. The strongest correlation was a negative correlation between MUFAs and
262 PUFAs/MUFAs ($r_g = -0.99$) observed based on GWAS in both models 1 and 2 (Figures S5 and
263 S6). Notably, genetic correlations between omega-6 PUFAs and omega-6% were negative in
264 models 1 ($r_g = -0.38$) and 2 ($r_g = -0.51$), but they were positively correlated in model 3 ($r_g = 0.34$)
265 after adjustment for lipoprotein lipids (Figure S7). Within omega-3-related traits, genetic
266 correlations were strong (~ 0.9) across all three models, with even stronger correlations found in
267 model 3. We also estimated pairwise phenotypic correlations using Pearson's correlation
268 coefficient (Table S13). Among significant genetic correlations, all pairs had consistent directions
269 compared to phenotypic correlations in models 1 and 2, while 83% of pairs had consistent
270 directions in model 3, suggesting that genetic effects on FA traits were altered after adding
271 lipoprotein lipids as covariates.

272 **Colocalization of GWAS signals across FA traits**

273 To assess the probability that two FA traits share the same causal variants, we conducted
274 pairwise colocalization analyses. For the 171 pairs of FA traits, we identified 9–231 colocalized
275 signals in model 2 and 6–114 in model 3, respectively. We found that pairs with a larger number
276 of colocalized signals also had stronger genetic correlations (Figure S8). In model 2, potential
277 causal variants in *DOCK7* (rs2934744), *GCKR* (rs1260326), *ZNF259* (rs964184), *FADSI*
278 (rs174564), *CPT1A* (rs2229738), *LIPC* (rs2070895), *LIPG* (rs77960347), *LDLR* (rs73015024),
279 *TM6SF2* (rs58542926), and *APOE* (rs7412) showed robust evidence of colocalization, indicating

280 shared genetic variants for pairs of FA traits (Table S14). After accounting for lipoprotein lipids
281 in model 3, *FADS1* (rs174564), *CPT1A* (rs2229738), and *BUD13* (chr11:116623213:TA:T) were
282 identified as colocalized and potentially causal signals for FA traits, with results consistent with
283 those from model 2 (Table S15). Next, we performed multi-trait colocalization analyses to evaluate
284 the posterior probability of a shared genetic signal across all FA traits. Overall, 168 and 159
285 colocalized signals were identified in models 2 and 3, respectively. We identified *GCKR*
286 (rs1260326), *TRIB1* (rs28601761), *FADS1* (rs174564), *ZNF259* (rs964184), and *APOE* (rs7412)
287 as shared between multiple FA traits in model 2 (Table S16), and *GCKR* (rs1260326), *TRIB1*
288 (rs28601761), *FADS1* (rs174564), and *APOE* (rs1065853) from model 3 as shared signals (Table
289 S17).

290 **Statistical fine-mapping for candidate causal variants**

291 We applied the Bayesian fine-mapping method to identify putative causal variants for FA
292 traits. We identified 477 unique potential causal variants in model 1, 422 in model 2, and 193 in
293 model 3 (Table S18). Consistent with colocalization analysis, we confirmed that the genetic
294 variants at the loci *TRIB1* (rs28601761), *FADS1* (rs174564), *CPT1A* (rs2229738), *LIPC*
295 (rs2070895), *LIPG* (rs77960347), *LDLR* (rs72658867), *TM6SF2* (rs58542926), and *APOE* (rs7412)
296 are likely to be causally associated with FA traits. Notably, we found that several loci contain
297 multiple 95% credible sets, indicating the existence of multiple potential causal variants within
298 those significant loci. Among the novel loci for FA traits, we found that *ZMIZ1* (rs1782652) was
299 associated with total FAs, total PUFAs, and omega-3 PUFAs, suggesting that it is a candidate
300 shared causal variant for these FAs. Additional potential causal variants for novel loci were
301 identified, including *CPS1* (rs1047891), *ATXN7L1* (rs118061830), *ARID5B* (rs77044968), *SBF2*

302 (rs12789941), *DGKZ* (rs149903077), *CYFIP1* (rs199854211), *FAM96A* (rs62023393), *MIR122*
303 (rs41292412), *BCL2* (rs12454712), *INSR* (rs112630404), and *PEPD* (rs62102718).

304 **Gene-based and gene-set analyses**

305 In the genome-wide gene-based association study, 139–541 genes from model 2 and 110–
306 255 genes from model 3 were found to be significantly associated with 19 FA traits after
307 Bonferroni correction (Table S19). The top gene across 19 FA traits identified in model 2 was
308 *ALDH1A2* (chr15: 58245622-58790065), which overlaps with another identified gene *LIPC*
309 (chr15: 58702768-58861151). In the GWAS of the omega-3/omega-6 ratio using model 3, *STH*
310 was the top gene, which might be related to neurodegenerative diseases such as Alzheimer's
311 disease.⁷¹ Gene-tissue expression analysis revealed that the liver was the most significantly
312 enriched tissue, followed by whole blood, kidney, small intestine, spleen, nerve, and adipose tissue
313 (Tables S20 and 21). Additionally, gene set analysis was performed to investigate potential gene
314 pathways (Tables S22 and 23). We detected those genes associated with total PUFAs clustered in
315 biological processes related to lipid homeostasis, secondary alcohol metabolism, organic hydroxy
316 compound transport, regulations of plasma lipoprotein particle levels and lipid metabolism, and
317 fatty acid biosynthesis (Figure 3). Fatty acid metabolic and biosynthetic processes were
318 significantly enriched in the gene set analysis results from GWAS of total PUFAs using model 3
319 (Figure S9).

320 **OPERA identifies intermediate molecular phenotypes underlying FA-associated loci**

321 To better understand the biological mechanisms of our GWAS findings, we applied
322 OPERA to explore the overlap of GWAS signals for FA traits and QTL signals for six molecular
323 phenotypes, including eQTL, pQTL, mQTL, sQTL, hQTL, and caQTL. With a PPA threshold of
324 0.9 and a P_{HEIDI} threshold of 0.01, we identified 976 FA-associated variants that overlap with QTL

325 signals for 2,106 unique molecular phenotype measures, including the expression levels of 242
326 genes, the abundance levels of 60 proteins, the methylation levels at 1,254 DNA sites, the RNA
327 splicing events at 141 sites, the status of 233 histone marks, and the openness at 176 chromatin
328 accessibility peaks (Figure 4A and Table S24). Overlaps with xQTL signals were also observed
329 for a large number of loci after adjusting for lipoprotein lipids in GWAS (Figure 4B and Table
330 S25). Associations with DNA methylation were more frequent than with other molecular
331 phenotypes, and these findings were consistent with previous results in other complex traits.⁶¹ The
332 number of loci associated with eQTL across 19 traits ranged from 7 for the degree of unsaturation
333 to 68 for PUFAs in model 2, and from 2 to 41 in model 3. Using the pQTL data from UKB-PPP,
334 we observed that 33 loci for omega-3 PUFAs from models 2 and 3 had the highest number of
335 significant associations with proteins.

336 We found that approximately 65% of GWAS loci for 19 FA traits are shared with at least
337 one molecular phenotype. Among the well-known FA loci, the potential causal variant rs174564
338 was found to overlap with QTL signals for the expression level of *MYRF* (ENSG00000124920)
339 and the methylation level at cg01825921. Across FA traits such as total FAs, total PUFAs, omega-
340 6 PUFAs, and total SFAs, the potential causal variant rs72658867, annotated at the *LDLR* gene,
341 was associated with histone modification (chr19:11105519-11214483) and chromatin accessibility
342 (peak 264429). Among the novel loci for omega-6%, rs149903077 (*DGKZ*) was jointly associated
343 with the nearby gene *NRIH3* (ENSG00000025434), histone modification (chr11:47234446-
344 47272168), and chromatin accessibility (peak 200213). It was also marginally associated with
345 methylation (cg01183595).

346 Notably, all six molecular phenotypes were jointly associated with total FAs, omega-6%,
347 and total MUFAs at the novel locus *GSTTP1* or nearby genes on chromosome 22 (Figure 5). We

348 observed that variant rs189660333 was associated with omega-3% jointly with five other types of
349 molecular phenotypes, except for histone modification. The nearby variants rs12786457 and
350 rs184864731 were consistently associated with these five phenotypes across GWAS related to
351 omega-3 PUFAs and the omega-3/omega-6 ratio. Overall, OPERA integrates six types of xQTL
352 data to offer mechanistic insights into genetic loci and their downstream molecular phenotypes.

353 **Discussion**

354 We performed overall and sex-specific GWAS for 19 FA traits in 250,101 UKB
355 participants of EUR descent and five other ancestry groups, separately. We identified 215, 163,
356 and 119 significant loci for PUFAs-, MUFAs-, and SFAs-related traits, including 70, 61, and 54
357 novel loci, respectively, in our primary model (i.e., model 2). Adjusting for lipoprotein lipids
358 dramatically reduce the number of GWAS signals. Our analyses of genetic correlations and
359 colocalization revealed the levels of shared genetic basis and specific candidate shared variants
360 across FA traits. Using statistical fine-mapping, we identified 422 putative causal variants across
361 all FA traits. Gene-based and gene-set analyses pinpointed the liver as the most relevant tissue and
362 highlighted biological pathways underlying FA loci. In addition, we integrated GWAS signals with
363 QTL signals for six molecular phenotypes and revealed that approximately 65% of GWAS loci for
364 19 FA traits are shared with at least one molecular phenotype, offering novel mechanistic insights.

365 In EUR GWAS, we analyzed 19 plasma NMR measures of FAs from 239,268 participants
366 in the UKB. Although previous GWAS of FA traits in the UKB reported many loci, we identified
367 approximately 90% more loci with a doubled sample size.^{29,32,33} In addition, we compared our
368 results with all previous GWAS of FAs-related traits to identify novel loci, including the second-
369 largest published GWAS to date, which included 136,016 participants from 33 cohorts.³⁷ We
370 calculated the omega-3/omega-6 and PUFA/SFA ratios for GWAS for the first time. Although the
371 omega-6 to omega-3 ratio is commonly used in studies, the omega-3/omega-6 ratio may better
372 capture the benefits of omega-3. This is particularly relevant given the ongoing debate over the
373 potential harmful or beneficial effects of omega-6 PUFAs.⁷² Our large GWAS of FAs showed that
374 the phenotypic variance explained by all SNPs ranged from 5–19%, while heritability estimates
375 from twin studies were approximately 25–62%.¹⁴ These results suggest that future studies with

376 rare or structural variants from sequencing and more diverse ancestry groups could be valuable for
377 identifying additional loci for FA traits.

378 Variants in the *FADS* gene cluster are well-known for modifying polyunsaturated fatty acid
379 desaturation, but the underlying molecular mechanisms require investigation. Using OPERA, we
380 identified the potential causal variant rs174564 in *FADS1*, which is associated with the *MYRF* gene
381 and the methylation site cg01825921. The *LDLR* gene variant rs72658867 was linked to histone
382 modification (19:11105519:11214483) and chromatin accessibility (264429), impacting lipid
383 metabolism and cardiovascular health.⁷³ The variant rs149903077 in the novel *DGKZ* locus has
384 been associated with the nearby gene *NRIH3*, chromatin accessibility, histone modifications, and
385 DNA methylation, highlighting their combined roles in nuclear receptor regulation, lipid
386 metabolism, and immune responses.⁷⁴ The novel *GSTTP1* locus, or nearby genes on chromosome
387 22, overlapped with all six molecular phenotypes and has been linked to key biological processes
388 such as detoxification, cancer susceptibility, and cellular responses to oxidative stress.⁷⁵

389 Gene set analysis findings highlight biological pathways underlying FA loci, implicating
390 lipid homeostasis, transport, and metabolism, and providing genetic support for the current
391 understanding of fatty acid regulation.⁷⁶ Our previous study suggested that lower omega-6% may
392 reduce alcohol consumption, with the secondary alcohol metabolism pathway potentially
393 explaining this effect on alcohol-related behaviors.⁶ In model 3, which adjusts for lipoprotein lipid
394 levels, fatty acid metabolic and biosynthetic processes were significantly more enriched in the
395 gene set analysis of GWAS of total PUFAs. The investigation of the disparities between models 2
396 and 3 suggests that lipoprotein-related biomarkers play a critical role in FA loci. Future studies are
397 needed to thoroughly dissect these roles, and further analyses, such as Mendelian randomization,

398 should properly infer results using genetic variants with or without adjustment for lipoprotein-
399 related biomarkers.⁷⁸

400 We investigated the sex-specific genetic architecture of FA traits. A novel locus,
401 *KRT18P55*, was identified in the GWAS for females, and previous research indicates that this
402 locus is highly expressed in patients with gastric cancer.⁷⁹ Notably, only one X-chromosomal locus
403 was identified in the male-only GWAS for omega-3%, tagged by the lead variants rs147828433
404 (closest protein-coding gene: *ACOT9*). A study on *ACOT9* in mice suggests that it regulates both
405 fatty acid and amino acid metabolism in mitochondria.⁸⁰ For the female-only GWAS, the
406 heritability was higher and larger numbers of loci were identified. Our results highlight the
407 importance of tracking sex differences in genetics and may motivate future studies on gene-sex
408 interactions. We found higher plasma PUFA levels in females, consistent with previous studies,
409 which were influenced by genetic effects, sex hormones, and conversion rates in FA metabolism.⁹
410 Randomized controlled trials show sex- and race-specific differences in the benefits of fish oil
411 supplementation and omega-3 PUFAs for preventing cardiovascular events and cognitive
412 decline.⁸¹

413 By performing ancestry-specific and sex-specific GWAS in non-EUR samples, we
414 identified additional novel loci, suggesting ancestry-specific genetic architecture of FA traits. In
415 male CSA participants, the novel locus *EDNI*, associated with omega-6 PUFA traits, encodes the
416 protein endothelin 1, which has been linked to cardiovascular events and prognosis.⁸² Variants in
417 *VPS39*, associated with omega-6 PUFAs in the CSA population, have been previously identified
418 as important regulators of myoblast differentiation and muscle glucose uptake in patients with type
419 2 diabetes.⁸³ Besides these ancestry-specific signals, we also found several loci identified from
420 large EUR GWAS were transferable to other ancestry groups, including *FADS2*, *ZNF259*, *MYRF*,

421 *APOA5*, *GCKR*, *APOE*, and other loci. We found significantly fewer loci in the other five non-
422 EUR ancestry GWAS due to small sample sizes. These results suggest that future studies with
423 larger and more diverse ancestry samples are needed to identify more loci and confirm their
424 consistency across populations.

425 To the best of our knowledge, our study is the most comprehensive GWAS on FA traits in
426 a very large cohort. First, this is the first study to integrate six types of xQTL data with FA GWAS
427 to explore the possible molecular mechanisms of FA-associated genetic variants. Second, we used
428 a large number of participants of EUR ancestry with plasma NMR measures for 19 FA traits and
429 included participants from five other ancestry groups. Third, the inclusion of the omega-3/omega-
430 6 ratio in the GWAS provides better insights into the benefits of omega-3 PUFAs. Fourth, our sex-
431 specific GWAS on EUR and non-EUR populations, as well as identified X-chromosomal loci,
432 uncover sex differences in FA genetic basis. Fifth, we comprehensively compared our findings to
433 all previous GWAS of FAs-related traits. Detailed information on all novel and known loci has
434 been provided (Tables S5 and S7), which offers a good resource for researchers to further explore
435 FAs-related loci. Finally, we adjusted for various covariates across three models, with a particular
436 focus on genetic architecture adjusted for lipoprotein metabolism.

437 The study has limitations. The number of participants from non-EUR populations was low,
438 and future studies with larger sample sizes are necessary. While we explored the molecular
439 mechanisms of FA loci, we are eager to extend OPERA analysis to other tissues, particularly the
440 liver, and even specific cell types, to identify cell type-specific disease mechanisms.

441 In conclusion, our findings reveal novel genetic loci and provide the first evidence of
442 molecular mechanisms underlying FA-relevant variants. These insights could aid patient

443 stratification for precision nutrition and the identification of novel therapeutic targets for FAs-
444 related diseases.

445 **Data availability**

446 The full summary statistics for GWAS of fatty acids will be publicly available in the GWAS
447 Catalog database (<https://www.ebi.ac.uk/gwas/>). The blood eQTL data of eQTLGen Consortium
448 used in the analyses were downloaded from [https://molgenis26.gcc.rug.nl/downloads/eqtlgen/cis-](https://molgenis26.gcc.rug.nl/downloads/eqtlgen/cis-eqtl/SMR_formatted/cis-eQTL-tar.gz)
449 [eqtl/SMR_formatted/cis-eQTL-](https://molgenis26.gcc.rug.nl/downloads/eqtlgen/cis-eqtl/SMR_formatted/cis-eQTL-tar.gz)
450 [https://zenodo.org/records/7951839/files/LBC_BSGS_meta.tar.gz?download=1SMR_20191212.](https://zenodo.org/records/7951839/files/LBC_BSGS_meta.tar.gz?download=1SMR_20191212.tar.gz)
451 [tar.gz](https://zenodo.org/records/7951839/files/LBC_BSGS_meta.tar.gz?download=1SMR_20191212.tar.gz). UKBB pQTL data are available at <https://metabolomips.org/ukbbpgwas/>. The mQTL data
452 are available for download from
453 https://zenodo.org/records/7951839/files/LBC_BSGS_meta.tar.gz?download=1. Blood sQTL
454 data can be downloaded at
455 [https://yanglab.westlake.edu.cn/data/SMR/GTEEx_V8_cis_sqtl_summary/sQTL_Whole_Blood.zi](https://yanglab.westlake.edu.cn/data/SMR/GTEEx_V8_cis_sqtl_summary/sQTL_Whole_Blood.zip)
456 [p](https://yanglab.westlake.edu.cn/data/SMR/GTEEx_V8_cis_sqtl_summary/sQTL_Whole_Blood.zip). The hQTL data can be assessed from
457 http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/qtl_as/QTL_RESULTS/. Summary
458 statistics of caQTL can be found at <https://zenodo.org/records/1405945/files/>.

459 **Acknowledgments**

460 This research was approved by the University of Georgia Institutional Review Board and the UK
461 Biobank consortium (application no. 48818). This work was funded by the University of Georgia
462 Research Foundation and by the National Institute of General Medical Sciences of the National
463 Institutes of Health under Award Number R35GM143060. The content is solely the responsibility
464 of the authors and does not necessarily represent the official views of the National Institutes of
465 Health.

466 **Author contributions**

467 Y.S. and K.Y. designed the study. Y.S. and H.X. performed analyses. Y.S. and K.Y. drafted the
468 manuscript. All authors contributed to the review and critical revision of the manuscript.

469 **Declaration of interests**

470 The authors declare no competing interests.

References

- 471 1. Worthmann, A., Ridder, J., Piel, S.Y.L., Evangelakos, I., Musfeldt, M., Voss, H.,
472 O'Farrell, M., Fischer, A.W., Adak, S., Sundd, M., et al. (2024). Fatty acid synthesis
473 suppresses dietary polyunsaturated fatty acid use. *Nat Commun* 15, 45. 10.1038/s41467-
474 023-44364-y.
- 475 2. Baum, S.J., Kris-Etherton, P.M., Willett, W.C., Lichtenstein, A.H., Rudel, L.L., Maki,
476 K.C., Whelan, J., Ramsden, C.E., and Block, R.C. (2012). Fatty acids in cardiovascular
477 health and disease: a comprehensive update. *J Clin Lipidol* 6, 216-234.
478 10.1016/j.jacl.2012.04.077.
- 479 3. Astrup, A., Magkos, F., Bier, D.M., Brenna, J.T., de Oliveira Otto, M.C., Hill, J.O., King,
480 J.C., Mente, A., Ordovas, J.M., Volek, J.S., et al. (2020). Saturated Fats and Health: A
481 Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art
482 Review. *J Am Coll Cardiol* 76, 844-857. 10.1016/j.jacc.2020.05.077.
- 483 4. Scorletti, E., and Byrne, C.D. (2013). Omega-3 fatty acids, hepatic lipid metabolism, and
484 nonalcoholic fatty liver disease. *Annu Rev Nutr* 33, 231-248. 10.1146/annurev-nutr-
485 071812-161230.
- 486 5. Zhang, Y., Sun, Y., Yu, Q., Song, S., Brenna, J.T., Shen, Y., and Ye, K. (2024). Higher
487 ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause,
488 cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank.
489 *Elife* 12. 10.7554/eLife.90132.
- 490 6. Xu, H., Sun, Y., Francis, M., Cheng, C.F., Modulla, N.T.R., Brenna, J.T., Chiang,
491 C.W.K., and Ye, K. (2023). Shared genetic basis informs the roles of polyunsaturated
492 fatty acids in brain disorders. medRxiv. 10.1101/2023.10.03.23296500.
- 493 7. Sun, Y., Chatterjee, R., Ronanki, A., and Ye, K. (2022). Circulating Polyunsaturated
494 Fatty Acids and COVID-19: A Prospective Cohort Study and Mendelian Randomization
495 Analysis. *Front Med (Lausanne)* 9, 923746. 10.3389/fmed.2022.923746.
- 496 8. Hodson, L., Skeaff, C.M., and Fielding, B.A. (2008). Fatty acid composition of adipose
497 tissue and blood in humans and its use as a biomarker of dietary intake. *Prog Lipid Res*
498 47, 348-380. 10.1016/j.plipres.2008.03.003.
- 499 9. Decsi, T., and Kennedy, K. (2011). Sex-specific differences in essential fatty acid
500 metabolism. *Am J Clin Nutr* 94, 1914S-1919S. 10.3945/ajcn.110.000893.
- 501 10. Mathias, R.A., Pani, V., and Chilton, F.H. (2014). Genetic Variants in the FADS Gene:
502 Implications for Dietary Recommendations for Fatty Acid Intake. *Curr Nutr Rep* 3, 139-
503 148. 10.1007/s13668-014-0079-1.
- 504 11. Zhuang, P., Liu, X., Li, Y., Wu, Y., Li, H., Wan, X., Zhang, L., Xu, C., Jiao, J., and
505 Zhang, Y. (2023). Circulating fatty acids, genetic risk, and incident coronary artery
506 disease: A prospective, longitudinal cohort study. *Sci Adv* 9, eadf9037.
507 10.1126/sciadv.adf9037.
- 508 12. Tanaka, T., Shen, J., Abecasis, G.R., Kisiailiou, A., Ordovas, J.M., Guralnik, J.M.,
509 Singleton, A., Bandinelli, S., Cherubini, A., Arnett, D., et al. (2009). Genome-wide
510 association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. *PLoS*
511 *Genet* 5, e1000338. 10.1371/journal.pgen.1000338.
- 512 13. Lemaitre, R.N., Tanaka, T., Tang, W., Manichaikul, A., Foy, M., Kabagambe, E.K.,
513 Nettleton, J.A., King, I.B., Weng, L.C., Bhattacharya, S., et al. (2011). Genetic loci
514 associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide

- 515 association studies from the CHARGE Consortium. *PLoS Genet* 7, e1002193.
516 [10.1371/journal.pgen.1002193](https://doi.org/10.1371/journal.pgen.1002193).
- 517 14. Kettunen, J., Tukiainen, T., Sarin, A.P., Ortega-Alonso, A., Tikkanen, E., Lyytikäinen,
518 L.P., Kangas, A.J., Soininen, P., Wurtz, P., Silander, K., et al. (2012). Genome-wide
519 association study identifies multiple loci influencing human serum metabolite levels. *Nat*
520 *Genet* 44, 269-276. [10.1038/ng.1073](https://doi.org/10.1038/ng.1073).
- 521 15. Wu, J.H., Lemaitre, R.N., Manichaikul, A., Guan, W., Tanaka, T., Foy, M., Kabagambe,
522 E.K., Djousse, L., Siscovick, D., Fretts, A.M., et al. (2013). Genome-wide association
523 study identifies novel loci associated with concentrations of four plasma phospholipid
524 fatty acids in the de novo lipogenesis pathway: results from the Cohorts for Heart and
525 Aging Research in Genomic Epidemiology (CHARGE) consortium. *Circ Cardiovasc*
526 *Genet* 6, 171-183. [10.1161/CIRCGENETICS.112.964619](https://doi.org/10.1161/CIRCGENETICS.112.964619).
- 527 16. Guan, W., Steffen, B.T., Lemaitre, R.N., Wu, J.H.Y., Tanaka, T., Manichaikul, A., Foy,
528 M., Rich, S.S., Wang, L., Nettleton, J.A., et al. (2014). Genome-wide association study of
529 plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research in
530 genomic epidemiology consortium. *Circ Cardiovasc Genet* 7, 321-331.
531 [10.1161/CIRCGENETICS.113.000208](https://doi.org/10.1161/CIRCGENETICS.113.000208).
- 532 17. Lemaitre, R.N., King, I.B., Kabagambe, E.K., Wu, J.H., McKnight, B., Manichaikul, A.,
533 Guan, W., Sun, Q., Chasman, D.I., Foy, M., et al. (2015). Genetic loci associated with
534 circulating levels of very long-chain saturated fatty acids. *J Lipid Res* 56, 176-184.
535 [10.1194/jlr.M052456](https://doi.org/10.1194/jlr.M052456).
- 536 18. Tintle, N.L., Pottala, J.V., Lacey, S., Ramachandran, V., Westra, J., Rogers, A., Clark, J.,
537 Olthoff, B., Larson, M., Harris, W., and Shearer, G.C. (2015). A genome-wide
538 association study of saturated, mono- and polyunsaturated red blood cell fatty acids in the
539 Framingham Heart Offspring Study. *Prostaglandins Leukot Essent Fatty Acids* 94, 65-72.
540 [10.1016/j.plefa.2014.11.007](https://doi.org/10.1016/j.plefa.2014.11.007).
- 541 19. Dorajoo, R., Sun, Y., Han, Y., Ke, T., Burger, A., Chang, X., Low, H.Q., Guan, W.,
542 Lemaitre, R.N., Khor, C.C., et al. (2015). A genome-wide association study of n-3 and n-
543 6 plasma fatty acids in a Singaporean Chinese population. *Genes Nutr* 10, 53.
544 [10.1007/s12263-015-0502-2](https://doi.org/10.1007/s12263-015-0502-2).
- 545 20. Hu, Y., Li, H., Lu, L., Manichaikul, A., Zhu, J., Chen, Y.D., Sun, L., Liang, S.,
546 Siscovick, D.S., Steffen, L.M., et al. (2016). Genome-wide meta-analyses identify novel
547 loci associated with n-3 and n-6 polyunsaturated fatty acid levels in Chinese and
548 European-ancestry populations. *Hum Mol Genet* 25, 1215-1224. [10.1093/hmg/ddw002](https://doi.org/10.1093/hmg/ddw002).
- 549 21. Kettunen, J., Demirkan, A., Wurtz, P., Draisma, H.H., Haller, T., Rawal, R., Vaarhorst,
550 A., Kangas, A.J., Lyytikäinen, L.P., Pirinen, M., et al. (2016). Genome-wide study for
551 circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. *Nat*
552 *Commun* 7, 11122. [10.1038/ncomms11122](https://doi.org/10.1038/ncomms11122).
- 553 22. Kalsbeek, A., Veenstra, J., Westra, J., Disselkoen, C., Koch, K., McKenzie, K.A., O'Bott,
554 J., Vander Woude, J., Fischer, K., Shearer, G.C., et al. (2018). A genome-wide
555 association study of red-blood cell fatty acids and ratios incorporating dietary covariates:
556 Framingham Heart Study Offspring Cohort. *PLoS One* 13, e0194882.
557 [10.1371/journal.pone.0194882](https://doi.org/10.1371/journal.pone.0194882).
- 558 23. de Oliveira Otto, M.C., Lemaitre, R.N., Sun, Q., King, I.B., Wu, J.H.Y., Manichaikul, A.,
559 Rich, S.S., Tsai, M.Y., Chen, Y.D., Fornage, M., et al. (2018). Genome-wide association

- 560 meta-analysis of circulating odd-numbered chain saturated fatty acids: Results from the
561 CHARGE Consortium. *PLoS One* *13*, e0196951. [10.1371/journal.pone.0196951](https://doi.org/10.1371/journal.pone.0196951).
- 562 24. Marklund, M., Morris, A.P., Mahajan, A., Ingelsson, E., Lindgren, C.M., Lind, L., and
563 Riserus, U. (2018). Genome-Wide Association Studies of Estimated Fatty Acid
564 Desaturase Activity in Serum and Adipose Tissue in Elderly Individuals: Associations
565 with Insulin Sensitivity. *Nutrients* *10*. [10.3390/nu10111791](https://doi.org/10.3390/nu10111791).
- 566 25. Locke, A.E., Steinberg, K.M., Chiang, C.W.K., Service, S.K., Havulinna, A.S., Stell, L.,
567 Pirinen, M., Abel, H.J., Chiang, C.C., Fulton, R.S., et al. (2019). Exome sequencing of
568 Finnish isolates enhances rare-variant association power. *Nature* *572*, 323-328.
569 [10.1038/s41586-019-1457-z](https://doi.org/10.1038/s41586-019-1457-z).
- 570 26. Coltell, O., Sorli, J.V., Asensio, E.M., Barragan, R., Gonzalez, J.I., Gimenez-Alba, I.M.,
571 Zanon-Moreno, V., Estruch, R., Ramirez-Sabio, J.B., Pascual, E.C., et al. (2020).
572 Genome-Wide Association Study for Serum Omega-3 and Omega-6 Polyunsaturated
573 Fatty Acids: Exploratory Analysis of the Sex-Specific Effects and Dietary Modulation in
574 Mediterranean Subjects with Metabolic Syndrome. *Nutrients* *12*. [10.3390/nu12020310](https://doi.org/10.3390/nu12020310).
- 575 27. Riveros-Mckay, F., Oliver-Williams, C., Karthikeyan, S., Walter, K., Kundu, K.,
576 Ouwehand, W.H., Roberts, D., Di Angelantonio, E., Soranzo, N., Danesh, J., et al.
577 (2020). The influence of rare variants in circulating metabolic biomarkers. *PLoS Genet*
578 *16*, e1008605. [10.1371/journal.pgen.1008605](https://doi.org/10.1371/journal.pgen.1008605).
- 579 28. Li-Gao, R., Hughes, D.A., van Klinken, J.B., de Mutsert, R., Rosendaal, F.R., Mook-
580 Kanamori, D.O., Timpson, N.J., and Willems van Dijk, K. (2021). Genetic Studies of
581 Metabolomics Change After a Liquid Meal Illuminate Novel Pathways for Glucose and
582 Lipid Metabolism. *Diabetes* *70*, 2932-2946. [10.2337/db21-0397](https://doi.org/10.2337/db21-0397).
- 583 29. Richardson, T.G., Leyden, G.M., Wang, Q., Bell, J.A., Elsworth, B., Davey Smith, G.,
584 and Holmes, M.V. (2022). Characterising metabolomic signatures of lipid-modifying
585 therapies through drug target mendelian randomisation. *PLoS Biol* *20*, e3001547.
586 [10.1371/journal.pbio.3001547](https://doi.org/10.1371/journal.pbio.3001547).
- 587 30. Yin, X., Chan, L.S., Bose, D., Jackson, A.U., VandeHaar, P., Locke, A.E., Fuchsberger,
588 C., Stringham, H.M., Welch, R., Yu, K., et al. (2022). Genome-wide association studies
589 of metabolites in Finnish men identify disease-relevant loci. *Nat Commun* *13*, 1644.
590 [10.1038/s41467-022-29143-5](https://doi.org/10.1038/s41467-022-29143-5).
- 591 31. Montasser, M.E., Aslibekyan, S., Srinivasasainagendra, V., Tiwari, H.K., Patki, A.,
592 Bagheri, M., Kind, T., Barupal, D.K., Fan, S., Perry, J., et al. (2022). An Amish founder
593 population reveals rare-population genetic determinants of the human lipidome. *Commun*
594 *Biol* *5*, 334. [10.1038/s42003-022-03291-2](https://doi.org/10.1038/s42003-022-03291-2).
- 595 32. Francis, M., Sun, Y., Xu, H., Brenna, J.T., and Ye, K. (2022). Fifty-one novel and
596 replicated GWAS loci for polyunsaturated and monounsaturated fatty acids in 124,024
597 Europeans. *medRxiv*, 2022.2005.2027.22275343. [10.1101/2022.05.27.22275343](https://doi.org/10.1101/2022.05.27.22275343).
- 598 33. Borges, M.C., Haycock, P.C., Zheng, J., Hemani, G., Holmes, M.V., Davey Smith, G.,
599 Hingorani, A.D., and Lawlor, D.A. (2022). Role of circulating polyunsaturated fatty acids
600 on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid
601 genetic association data from over 114,000 UK Biobank participants. *BMC Med* *20*, 210.
602 [10.1186/s12916-022-02399-w](https://doi.org/10.1186/s12916-022-02399-w).
- 603 34. Liu, C., Wang, Z., Hui, Q., Chiang, Y., Chen, J., Brijkumar, J., Edwards, J.A., Ordonez,
604 C.E., Dudgeon, M.R., Sunpath, H., et al. (2022). Crosstalk between Host Genome and

- 605 Metabolome among People with HIV in South Africa. *Metabolites* 12.
606 10.3390/metabo12070624.
- 607 35. Davyson, E., Shen, X., Gadd, D.A., Bernabeu, E., Hillary, R.F., McCartney, D.L.,
608 Adams, M., Marioni, R., and McIntosh, A.M. (2023). Metabolomic Investigation of
609 Major Depressive Disorder Identifies a Potentially Causal Association With
610 Polyunsaturated Fatty Acids. *Biol Psychiatry* 94, 630-639.
611 10.1016/j.biopsych.2023.01.027.
- 612 36. Fuller, H., Iles, M.M., Moore, J.B., and Zulyniak, M.A. (2023). Metabolic drivers of
613 dysglycemia in pregnancy: ethnic-specific GWAS of 146 metabolites and 1-sample
614 Mendelian randomization analyses in a UK multi-ethnic birth cohort. *Front Endocrinol*
615 (Lausanne) 14, 1157416. 10.3389/fendo.2023.1157416.
- 616 37. Karjalainen, M.K., Karthikeyan, S., Oliver-Williams, C., Sliz, E., Allara, E., Fung, W.T.,
617 Surendran, P., Zhang, W., Jousilahti, P., Kristiansson, K., et al. (2024). Genome-wide
618 characterization of circulating metabolic biomarkers. *Nature* 628, 130-138.
619 10.1038/s41586-024-07148-y.
- 620 38. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott,
621 P., Green, J., Landray, M., et al. (2015). UK biobank: an open access resource for
622 identifying the causes of a wide range of complex diseases of middle and old age. *PLoS*
623 *Med* 12, e1001779. 10.1371/journal.pmed.1001779.
- 624 39. Pan-ancestry genetic analysis of the UK Biobank. <https://pan.ukbb.broadinstitute.org/>.
- 625 40. Julkunen, H., Cichonska, A., Slagboom, P.E., Wurtz, P., and Nightingale Health,
626 U.K.B.I. (2021). Metabolic biomarker profiling for identification of susceptibility to
627 severe pneumonia and COVID-19 in the general population. *Elife* 10.
628 10.7554/eLife.63033.
- 629 41. McCaw, Z.R., Lane, J.M., Saxena, R., Redline, S., and Lin, X. (2020). Operating
630 characteristics of the rank-based inverse normal transformation for quantitative trait
631 analysis in genome-wide association studies. *Biometrics* 76, 1262-1272.
632 10.1111/biom.13214.
- 633 42. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A.,
634 Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with
635 deep phenotyping and genomic data. *Nature* 562, 203-209. 10.1038/s41586-018-0579-z.
- 636 43. Jiang, L., Zheng, Z., Qi, T., Kemper, K.E., Wray, N.R., Visscher, P.M., and Yang, J.
637 (2019). A resource-efficient tool for mixed model association analysis of large-scale data.
638 *Nat Genet* 51, 1749-1755. 10.1038/s41588-019-0530-8.
- 639 44. International HapMap, C., Altshuler, D.M., Gibbs, R.A., Peltonen, L., Altshuler, D.M.,
640 Gibbs, R.A., Peltonen, L., Dermitzakis, E., Schaffner, S.F., Yu, F., et al. (2010).
641 Integrating common and rare genetic variation in diverse human populations. *Nature* 467,
642 52-58. 10.1038/nature09298.
- 643 45. Yang, J., Zaitlen, N.A., Goddard, M.E., Visscher, P.M., and Price, A.L. (2014).
644 Advantages and pitfalls in the application of mixed-model association methods. *Nat*
645 *Genet* 46, 100-106. 10.1038/ng.2876.
- 646 46. Jordan, H., Roderick, P., and Martin, D. (2004). The Index of Multiple Deprivation 2000
647 and accessibility effects on health. *J Epidemiol Community Health* 58, 250-257.
648 10.1136/jech.2003.013011.
- 649 47. Cleland, C., Ferguson, S., Ellis, G., and Hunter, R.F. (2018). Validity of the International
650 Physical Activity Questionnaire (IPAQ) for assessing moderate-to-vigorous physical

- 651 activity and sedentary behaviour of older adults in the United Kingdom. *BMC Med Res*
652 *Methodol* 18, 176. 10.1186/s12874-018-0642-3.
- 653 48. Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A.,
654 Flicek, P., Manolio, T., Hindorff, L., and Parkinson, H. (2014). The NHGRI GWAS
655 Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* 42, D1001-
656 1006. 10.1093/nar/gkt1229.
- 657 49. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J.,
658 McCarthy, M.I., Ramos, E.M., Cardon, L.R., Chakravarti, A., et al. (2009). Finding the
659 missing heritability of complex diseases. *Nature* 461, 747-753. 10.1038/nature08494.
- 660 50. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller,
661 J., Sklar, P., de Bakker, P.I., Daly, M.J., and Sham, P.C. (2007). PLINK: a tool set for
662 whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81,
663 559-575. 10.1086/519795.
- 664 51. McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., and Cunningham, F. (2010).
665 Deriving the consequences of genomic variants with the Ensembl API and SNP Effect
666 Predictor. *Bioinformatics* 26, 2069-2070. 10.1093/bioinformatics/btq330.
- 667 52. Bulik-Sullivan, B.K., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia
668 Working Group of the Psychiatric Genomics, C., Patterson, N., Daly, M.J., Price, A.L.,
669 and Neale, B.M. (2015). LD Score regression distinguishes confounding from
670 polygenicity in genome-wide association studies. *Nat Genet* 47, 291-295.
671 10.1038/ng.3211.
- 672 53. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.R.,
673 ReproGen, C., Psychiatric Genomics, C., Genetic Consortium for Anorexia Nervosa of
674 the Wellcome Trust Case Control, C., Duncan, L., et al. (2015). An atlas of genetic
675 correlations across human diseases and traits. *Nat Genet* 47, 1236-1241.
676 10.1038/ng.3406.
- 677 54. Weissbrod, O., Hormozdiari, F., Benner, C., Cui, R., Ulirsch, J., Gazal, S., Schoech, A.P.,
678 van de Geijn, B., Reshef, Y., Marquez-Luna, C., et al. (2020). Functionally informed
679 fine-mapping and polygenic localization of complex trait heritability. *Nat Genet* 52,
680 1355-1363. 10.1038/s41588-020-00735-5.
- 681 55. Loh, P.R., Kichaev, G., Gazal, S., Schoech, A.P., and Price, A.L. (2018). Mixed-model
682 association for biobank-scale datasets. *Nat Genet* 50, 906-908. 10.1038/s41588-018-
683 0144-6.
- 684 56. Foley, C.N., Staley, J.R., Breen, P.G., Sun, B.B., Kirk, P.D.W., Burgess, S., and Howson,
685 J.M.M. (2021). A fast and efficient colocalization algorithm for identifying shared
686 genetic risk factors across multiple traits. *Nat Commun* 12, 764. 10.1038/s41467-020-
687 20885-8.
- 688 57. Wang, G., Sarkar, A., Carbonetto, P., and Stephens, M. (2020). A simple new approach
689 to variable selection in regression, with application to genetic fine mapping. *J R Stat Soc*
690 *Series B Stat Methodol* 82, 1273-1300. 10.1111/rssb.12388.
- 691 58. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional
692 mapping and annotation of genetic associations with FUMA. *Nat Commun* 8, 1826.
693 10.1038/s41467-017-01261-5.
- 694 59. Lee, S.H., Wray, N.R., Goddard, M.E., and Visscher, P.M. (2011). Estimating missing
695 heritability for disease from genome-wide association studies. *Am J Hum Genet* 88, 294-
696 305. 10.1016/j.ajhg.2011.02.002.

- 697 60. Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., and
698 Mesirov, J.P. (2011). Molecular signatures database (MSigDB) 3.0. *Bioinformatics* 27,
699 1739-1740. [10.1093/bioinformatics/btr260](https://doi.org/10.1093/bioinformatics/btr260).
- 700 61. Wu, Y., Qi, T., Wray, N.R., Visscher, P.M., Zeng, J., and Yang, J. (2023). Joint analysis
701 of GWAS and multi-omics QTL summary statistics reveals a large fraction of GWAS
702 signals shared with molecular phenotypes. *Cell Genom* 3, 100344.
703 [10.1016/j.xgen.2023.100344](https://doi.org/10.1016/j.xgen.2023.100344).
- 704 62. Vosa, U., Claringbould, A., Westra, H.J., Bonder, M.J., Deelen, P., Zeng, B., Kirsten, H.,
705 Saha, A., Kreuzhuber, R., Yazar, S., et al. (2021). Large-scale cis- and trans-eQTL
706 analyses identify thousands of genetic loci and polygenic scores that regulate blood gene
707 expression. *Nat Genet* 53, 1300-1310. [10.1038/s41588-021-00913-z](https://doi.org/10.1038/s41588-021-00913-z).
- 708 63. Sun, B.B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.H., Richardson, T.G., Surendran,
709 P., Mahajan, A., Robins, C., Vasquez-Grinnell, S.G., et al. (2023). Plasma proteomic
710 associations with genetics and health in the UK Biobank. *Nature* 622, 329-338.
711 [10.1038/s41586-023-06592-6](https://doi.org/10.1038/s41586-023-06592-6).
- 712 64. Wu, Y., Zeng, J., Zhang, F., Zhu, Z., Qi, T., Zheng, Z., Lloyd-Jones, L.R., Marioni, R.E.,
713 Martin, N.G., Montgomery, G.W., et al. (2018). Integrative analysis of omics summary
714 data reveals putative mechanisms underlying complex traits. *Nat Commun* 9, 918.
715 [10.1038/s41467-018-03371-0](https://doi.org/10.1038/s41467-018-03371-0).
- 716 65. McRae, A.F., Marioni, R.E., Shah, S., Yang, J., Powell, J.E., Harris, S.E., Gibson, J.,
717 Henders, A.K., Bowdler, L., Painter, J.N., et al. (2018). Identification of 55,000
718 Replicated DNA Methylation QTL. *Sci Rep* 8, 17605. [10.1038/s41598-018-35871-w](https://doi.org/10.1038/s41598-018-35871-w).
- 719 66. Consortium, G.T. (2020). The GTEx Consortium atlas of genetic regulatory effects
720 across human tissues. *Science* 369, 1318-1330. [10.1126/science.aaz1776](https://doi.org/10.1126/science.aaz1776).
- 721 67. Chen, L., Ge, B., Casale, F.P., Vasquez, L., Kwan, T., Garrido-Martin, D., Watt, S., Yan,
722 Y., Kundu, K., Ecker, S., et al. (2016). Genetic Drivers of Epigenetic and Transcriptional
723 Variation in Human Immune Cells. *Cell* 167, 1398-1414 e1324.
724 [10.1016/j.cell.2016.10.026](https://doi.org/10.1016/j.cell.2016.10.026).
- 725 68. Kumasaka, N., Knights, A.J., and Gaffney, D.J. (2019). High-resolution genetic mapping
726 of putative causal interactions between regions of open chromatin. *Nat Genet* 51, 128-
727 137. [10.1038/s41588-018-0278-6](https://doi.org/10.1038/s41588-018-0278-6).
- 728 69. Goldstein, J.L., and Brown, M.S. (2009). The LDL receptor. *Arterioscler Thromb Vasc*
729 *Biol* 29, 431-438. [10.1161/ATVBAHA.108.179564](https://doi.org/10.1161/ATVBAHA.108.179564).
- 730 70. Naik, A., Kosir, R., and Rozman, D. (2013). Genomic aspects of NAFLD pathogenesis.
731 *Genomics* 102, 84-95. [10.1016/j.ygeno.2013.03.007](https://doi.org/10.1016/j.ygeno.2013.03.007).
- 732 71. Gao, L., Tse, S.W., Conrad, C., and Andreadis, A. (2005). Saitohin, which is nested in
733 the tau locus and confers allele-specific susceptibility to several neurodegenerative
734 diseases, interacts with peroxiredoxin 6. *J Biol Chem* 280, 39268-39272.
735 [10.1074/jbc.M506116200](https://doi.org/10.1074/jbc.M506116200).
- 736 72. Schulze, M.B., Minihane, A.M., Saleh, R.N.M., and Riserus, U. (2020). Intake and
737 metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications
738 for cardiometabolic diseases. *Lancet Diabetes Endocrinol* 8, 915-930. [10.1016/S2213-8587\(20\)30148-0](https://doi.org/10.1016/S2213-8587(20)30148-0).
- 740 73. Gretarsdottir, S., Helgason, H., Helgadottir, A., Sigurdsson, A., Thorleifsson, G.,
741 Magnusdottir, A., Oddsson, A., Steinthorsdottir, V., Rafnar, T., de Graaf, J., et al. (2015).
742 A Splice Region Variant in LDLR Lowers Non-high Density Lipoprotein Cholesterol and

- 743 Protects against Coronary Artery Disease. *PLoS Genet* *11*, e1005379.
744 10.1371/journal.pgen.1005379.
- 745 74. Raben, D.M., and Tu-Sekine, B. (2008). Nuclear diacylglycerol kinases: regulation and
746 roles. *Front Biosci* *13*, 590-597. 10.2741/2704.
- 747 75. Sadafi, S., Choubasaz, P., Kazemeini, S.M.M., Imani, M.M., and Sadeghi, M. (2024).
748 Glutathione S-transferase theta 1 (GSTT1) deletion polymorphism and susceptibility to
749 head and neck carcinoma: a systematic review with five analyses. *BMC Cancer* *24*, 885.
750 10.1186/s12885-024-12618-7.
- 751 76. Li, H., Herrmann, T., Seessle, J., Liebisch, G., Merle, U., Stremmel, W., and Chamulitrat,
752 W. (2022). Role of fatty acid transport protein 4 in metabolic tissues: insights into obesity
753 and fatty liver disease. *Biosci Rep* *42*. 10.1042/BSR20211854.
- 754 77. Sundaram, M., and Yao, Z. (2010). Recent progress in understanding protein and lipid
755 factors affecting hepatic VLDL assembly and secretion. *Nutr Metab (Lond)* *7*, 35.
756 10.1186/1743-7075-7-35.
- 757 78. Pingault, J.B., O'Reilly, P.F., Schoeler, T., Ploubidis, G.B., Rijdsdijk, F., and Dudbridge,
758 F. (2018). Using genetic data to strengthen causal inference in observational research.
759 *Nat Rev Genet* *19*, 566-580. 10.1038/s41576-018-0020-3.
- 760 79. Tayefeh-Gholami, S., Ghanbari, M., Aghazadeh, A., Rajabi, A., Saber, A., Hussien, B.M.,
761 Farsad-Akhtar, N., and Safaralizadeh, R. (2022). Prognostic Value of LncRNA
762 KRT18P55 in Patients with Intestinal Type of Gastric Cancer. *J Gastrointest Cancer* *53*,
763 1014-1019. 10.1007/s12029-021-00744-5.
- 764 80. Tillander, V., Arvidsson Nordstrom, E., Reilly, J., Strozyk, M., Van Veldhoven, P.P.,
765 Hunt, M.C., and Alexson, S.E. (2014). Acyl-CoA thioesterase 9 (ACOT9) in mouse may
766 provide a novel link between fatty acid and amino acid metabolism in mitochondria. *Cell*
767 *Mol Life Sci* *71*, 933-948. 10.1007/s00018-013-1422-1.
- 768 81. Welty, F.K., Daher, R., and Garelnabi, M. (2024). Fish and Omega-3 Fatty Acids: Sex
769 and Racial Differences in Cardiovascular Outcomes and Cognitive Function. *Arterioscler*
770 *Thromb Vasc Biol* *44*, 89-107. 10.1161/ATVBAHA.122.318125.
- 771 82. Jankowich, M., and Choudhary, G. (2020). Endothelin-1 levels and cardiovascular
772 events. *Trends Cardiovasc Med* *30*, 1-8. 10.1016/j.tcm.2019.01.007.
- 773 83. Davegardh, C., Sall, J., Benrick, A., Broholm, C., Volkov, P., Perfilyev, A., Henriksen,
774 T.I., Wu, Y., Hjort, L., Brons, C., et al. (2021). VPS39-deficiency observed in type 2
775 diabetes impairs muscle stem cell differentiation via altered autophagy and epigenetics.
776 *Nat Commun* *12*, 2431. 10.1038/s41467-021-22068-5.

Figure Captions

Main Figures

Figure 1. Manhattan plot of the genome-wide association studies for the absolute concentration of total polyunsaturated fatty acids. The association of each variant with polyunsaturated fatty acids was obtained from genome-wide association studies using models 2 (A) and 3 (B). A variant with a P -value below 5×10^{-8} was considered statistically significant. The nearest gene at each genome-wide significant locus is annotated, in black for known loci and in red for novel loci.

Figure 2. Miami plot of the absolute concentration of total polyunsaturated fatty acids from genome-wide association studies using model 2. The top panel shows the GWAS results in females, while the bottom panel shows the GWAS results in males. The $-\log_{10}(P\text{-value})$ is plotted on the y-axis and chromosomal location is plotted on the x-axis. The genome-wide significance threshold ($P\text{-value} < 5 \times 10^{-8}$) is indicated by the red dashed line. The nearest gene at each genome-wide significant locus is annotated, in black for known loci and in red for novel loci.

Figure 3. Pathway analysis of polyunsaturated fatty acids from genome-wide association studies using model 2. Treemap depicting significantly enriched pathways at an adjusted P -value threshold of 0.05. Gene ontology terms were clustered based on semantic similarity, with terms displayed as individual rectangles. The color indicates cluster membership, and thick border lines differentiate clusters. The size of each rectangle represents the enrichment significance, and the most significantly enriched term in each cluster is highlighted in white text as the representative term.

Figure 4. Number of loci for fatty acid traits associated with different molecular phenotype combinations. (A and B) The number of loci associated with 19 fatty acid traits and molecular quantitative trait loci (xQTLs) was determined based on genome-wide association studies using models 2 (A) and 3 (B). The loci numbers are based on significant OPERA association results that pass a posterior probability of association threshold of 0.9 and the multi-exposure heterogeneity in dependent instruments (HEIDI) test ($P_{\text{HEIDI}} > 0.01$). The x-axis represents the association hypotheses for different phenotype combinations, while the y-axis shows the number of loci associated with these combinations across 19 fatty acids. Each violin plot displays the distribution of loci numbers by width, with lines indicating the 25th percentile, median, and 75th percentile.

Figure 5. Prioritization of a locus near the *GSTT1/2/2B* genes for total fatty acids. The top track displays the $-\log_{10}(P\text{-value})$ of GWAS SNPs (gray dots) for total fatty acids. Red diamonds indicate OPERA marginal PPA for gene associations using eQTL data, while blue circles show OPERA marginal PPA for associations with DNA methylation, RNA splicing, histone modification, and chromatin accessibility, respectively. The bottom track presents 14 chromatin state annotations inferred from the 127 samples of the Roadmap Epigenomics Mapping Consortium.

Figure 1.




Figure 2.




Figure 3.



Figure 4.




Figure 5.

